Puma Biotechnology Initiates ALISCA®-Lung2, a Phase II Trial of Alisertib in Combination with Paclitaxel for the Treatment of Patients with Advanced Small Cell Lung Cancer
Business Wire•17/09/2026•16:07 ET
0
Get started
Create a free account to read the full story and Whiz Insights.